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Abstract 
Background: Pathogenic mycobacteria are one of major causes of human morbidity and mortality. Mycobacterium 
tuberculosis (M. tuberculosis) is an etiological agent of human tuberculosis. Designing new vaccines including DNA 
vaccines may be considered as new approaches for preventing of TB.  
Materials and Methods: M. tuberculosis H37Rv was grown on Lowenstein Jensen medium for 4 weeks at 37ºC 
and then DNA was extracted. The cfp10 gene was amplified by PCR. After digesting the PCR product and the 
plasmid, cfp10 fragment was ligated into the vector using T4 DNA ligase. Then, Ag85A was subcloned into 
pcDNA/cfp10. Escherichia coli strain JM109 bacteria were transformed by the desired construct. Clone 
confirmations were performed by colony PCR, restriction enzyme digestion and DNA sequencing. Recombinant 
vector was transfected into HeLa cells and total RNA was extracted, then cDNA was synthesized using oligo-dT. 
Finally PCR was performed by cfp10 primers.  
Results: The cfp10 was amplified by PCR method and the PCR products were visualized by agarose gel 
electrophoresis. The cfp10 fragments showed 303 bp in length. The cfp10 cloned into pcDNA. Then, Ag85Awas 
ligated into pcDNA/cfp10 after digestion correctly. Colony-PCR and restriction enzyme digestion and sequencing 
confirmed the cloning the fusion Ag85A/cfp10 fragment. Finally, after cDNA synthesis, expression of vector was 
confirmed in eukaryotic system.  
Conclusion: Cloning of Ag85A/cfp10 genes of M. tuberculosis were performed correctly. It can use as a DNA 
vaccine for investigation the immune responses in animal models in future studies. 
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Pathological cause of tuberculosis is 
Mycobacterium tuberculosis (M. tuberculosis) which 
is an optional intracellular bacterium. Tuberculosis 
(TB) is a worldwide public health problem that is 
often associated with AIDS and Malaria. M. 
tuberculosis are observed in  8 million new cases and 
cause 2 million deaths each year (1-4). 
Several strategies are being employed for the 
development of TB vaccines such as subunit vaccines, 
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recombinant BCG vaccines, auxotrophic vaccines, 
atypical mycobacterial strains, DNA vaccines and 
heterologous prime boost approach. Scientists around 
the world are looking for a suitable vaccine against 
M. tuberculosis due to the variable efficacy of BCG 
vaccine from zero to 80 percent and do not use it in 
patients who have a weakened immune system. 
Because of the low ability of BCG vaccine to 
stimulate CD8+ cells, some researchers have 
attributed this to the inability of BCG in infection 
control and they believe the vaccine design that could 
be create a memory CD8+ cells are helpful (5-8). 
BCG is a live attenuated strain of M. bovis and 
is the only available TB vaccine obtained almost one 
century ago. BCG offers significant protection 
against disseminated childhood tuberculosis, but is 
not true for the more prevalent adult pulmonary 
disease (9, 10). 
Currently there are a number of DNA vaccines 
in the clinical stages which have effects of prevention 
and treatment. Including the causes that impact on 
AIDS, herpes virus, influenza virus, malaria and 
cancer (11). 
Epitopes of DNA vaccine encode the protein 
sequences that bind to MHC molecules of human 
cells so that T-helper cells identify MHCπ-antigen 
complex and cytotoxic cells MHC I -antigen 
complex. Thus, DNA vaccines induce strong CD4+ 
(Th1) and (CTL) CD8 + against tuberculosis (12). In 
mice, several antigens M. tuberculosis provide 
immunity against infection including; Mtb 8.4, Ag85, 
MPT39, MPT63,  MPT83, Hsp65, PstS3, ESAT6, 
MPT64 and lipoprotein 38-kDa (13). 
The culture filtrate protein 10 (CFP10) and 
early secretory antigenic target protein 6 (ESAT6) 
are encoded by the RD1 genes Rv3874 and Rv3875 
of M. tuberculosis (14). Researchers demonstrated 
that CFP10 and ESAT6 might be biological active 
molecules in vivo when they form a 1:1 heterodimer 
complex. CFP10 and ESAT6 play an important role 
in M. tuberculosis virulence (15). Studies showed 
that the ESAT6 and CFP10 are highly immunogenic 
RD1 region, but not the overall protection (7). 
More testing of prepared DNA vaccine 
contain genes encoding the Ag85 family. All three 
members of this family have been studied as a DNA 
vaccine. Ag85A and Ag85B are active while Ag85C 
is not. Most studies are done on the Ag85A. In the late 
decade, DNA vaccine encoding Ag85A was produced. 
This antigen in contrast Ag85C is highly immunogenic 
and made safety protection in mice that were infected 
by aerosol with M. tuberculosis (7) Vaccination with 
DNA plasmid encoding Ag85A subunit leads to Th1 
and CTL cells strong responses (16). 
 Ag85 complex is fibronectin-binding and it is 
effective to induce protective immunity in animal 
models.  Three components of Ag85 complex are 32-
30 kDa proteins (Ag85A, Ag85B and Ag85C) (16), 
that belong to the vast majority of secretory proteins of 
M. tuberculosis and the BCG culture products Ag85A 
(Rv3804c) molecule is a major secretory protein of M. 
tuberculosis with a length of 295 amino acids in 
addition it has maykolyl transferase activity in the 
final stage of processing the cell wall of mycobacteria 
(16, 17). 121 to 145 amino acids (peptides 25 and 27) 
and 196 to 215 (peptides 40 and 41) make the largest 
immunogenicity (18). 
 Several experimental TB vaccines were 
constructed such as DNA vaccines expressing antigens 
from the RD1 and RD2 loci such as CFP10 and CFP21 
in combination with the secreted protein antigen 85B 
(19). 
Accordingly, vaccination with multiple antigens 
may improve in high protective effects. In the present 
study we focus on the Ag85A and cfp10 
immunodominant genes in order to produce a vaccine 
against M. tuberculosis H37Rv strain. 
Methods 
2.1 Cells and Plasmids. M. tuberculosis strain 
H37Rv obtained from the Pasteur Institute (Tehran, 
Iran) was used for isolation of cfp10 gene. Also, 
pCDNA3.1 (+) vector (Qiagen company, Germany) 
was used for cloning; pCDNA3.1/Ag85a (GENERAY 
company, China) was synthesized for our work and 
was used for subcloning. HeLa cells was used for 
transfection.  
2.2  Subcloning Ag85A in pcDNA cfp10. The 
pcDNA cfp10 was used for our work. This vector had 
been cloned in E. coli strain JM109 and transfected to 
HeLa cell (20). We subcloned Ag85a to pcDNA cfp10. 
For primer designing of Ag85A was done 
somethings. The upstream Ag85A inserted a unique 
restriction site BamHI and replaced the start codon of 
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the antigen gene with a Kozak consensus sequence 
(ACCATGG) to enhance mammalian expression. In 
the downstream Ag85A was removed the stop codon, 
and was inserted a second unique restriction site 
EcoRI. 
 The Ag85A gene (1036 bp fragment) from 
recombinant plasmid pcDNA Ag85A and also 
pCDNA cfp10 were digested with BamHI and EcoRI. 
The purification procedure was performed using 
protocol (Invisorb spin DNA extraction kit, 
Germany) and the products were detected by 1.5% 
agarose gel electrophoresis. 
The digested products were ligated to generate 
pCDNA Ag85A/cfp10 by T4 DNA ligase.  
E. coli strain JM109 in LB medium was 
transformed as noted above. Then, extraction of 
chimeric plasmid was done using the QIAprep 
Miniprep Kit (Qiagen company, USA).  
2.3Confirmation chimeric plasmid pcDNA 
Ag85A/cfp10 
2.3.1 Enzyme digestion. The chimeric plasmid 
was subsequently characterized by restriction 
enzyme digestion. To make ensuring of the correct 
orientation of the fragments, chimeric pcDNA 
Ag85A/cfp10 plasmid was digested by BamHI and 
EcoRI enzymes and then was electrophoresed on 1% 
agarose gel. In addition, the pcDNA Ag85A/cfp10 
was digested with BamHI and XbaI and in the next 
step with BamHI and EcoRI enzymes to confirm 
fusion two fragments of Ag85A/cfp10. 
2.3.2 Colony- PCR for cfp10. The second 
method for confirmation of cloning Ag85A into 
pcDNA cfp10 colony-PCR by cfp10 primers 
5’ATTGATAGAATTCGCAGAGATGAAGACCG
ATGCCGCT3’ (forward primer) and 
5'TCATTAATCTAGATTATCAGAAGCCCATTTG
CGAGGACAG 3' (reverse primer).  PCR mixture 
consisted of 10 pmol of each primer, MgCl2 1.5 mM, 
0.2 mM each dNTP, 5U Taq DNA polythermase 
(CinnaGen company, Iran) in a total reaction volume 
of 25 μl, then a tip of colony was dissolved. The 
following conditions were applied: initial 
denaturation at 95°C for 5 min, followed by 35 
cycles; denaturation at 95°C for 1 min, annealing at 
65°C for 1 min, elongation at 72° for 1 min. 
2.3.3 Sequencing. The fusion fragment 
containing Ag85A and cfp10 was sent for sequencing 
(Macrogen company, Korea) using the T7 forward (5' 
TAATACGACTCACTATAGGG 3') and BGH 
reverse (5' TAGAAGGCACAGTCGAGGC 3') 
primers. PCR reaction and it's program was the same 
of we did for cfp10 but the difference was at 52° C 
annealing temperature.  
2.4 Cell transfection. HeLa cells were cultured 
in DMEM medium supplemented with 10% fetal calf 
serum and 100 units/ml penicillin. The cell culture 
flask was incubated overnight at 37 ° C, 5% CO2. We 
checked the cell growth and when the cells reached a 
confluence level of approximately 70–80%, the 
transfection was performed. 
Actually the cells were transfected with 30 
ng/μl the pCDNA Ag85A/cfp10 expression vector in 
125 μl distilled deionized water (DDW) and 25 μl 
CaCl2 25mM reagent in a sterile microtube. Then 250 
μl 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) was added and was maintained in room 
temperature for 20 min. All of the contents of 
microtube was poured at cell plates and was incubated 
for 5h at 37 ° C. 
In the next step, the cells were plated in 6-well 
plates for two overnights at 37 ° C, 5% CO2 according 
to the protocol in Sambrook book. 
2.5 Confirmation of gene expression in 
eukaryotic system. The confirmation of Ag85A/cfp10 
mRNA expression was carried out by RT-PCR. 
RNA extraction was performed by using 10000 
transfected cells and 450 μl RNX
TM
-PLUS according 
to the protocol provided (CinnaGen Company, Iran). 
For cDNA synthesis, easy cDNA synthesis Kit was 
used (ParsToos Company, Iran). 
In the final step 1 μl DNase1, 1 μl Buffer B, 3 
μl Diethylpyrocarbonate (DEPC) water were added to 
5 μl of extracted RNA. Due to confirm our test, the 
similar sample above was selected the control case 
with exception that RNA plasmid was replaced by 
DNA plasmid (addition of RNase). We also used of 
untransfected HeLa cells as another negative control. 
Finally, the PCR reaction by cfp10 primers was 
performed to prove the pCDNA Ag85A/cfp10 
recombinant vector in HeLa cells had been expressed. 
Results 
Before subcloning, digestion of pcDNA cfp10 
with BamHI and EcoRI was showed 5700 bp fragment 
Baghani et al.                        Designing and construction a DNA vaccine encoding the fusion fragment of cfp10 and Ag85A … 





Figure 1. Analysis of digested fragments from pcDNA 
Ag85A/cfp10.  1) Double digestion with BamHI and XbaI 2) DNA 
size marker 1kbp (Fermentase company, Germany) 3) Double 




Figure 2. Colony-PCR for cfp10 gene. 303 bp band is related to cfp10 
fragment and DNA size marker is 1oo bp (Fermentase company, 
Germany) 
were related to digested linear pcDNA cfp10. 
Also the Ag85A was separated from pcDNA 
Ag85A so that Ag85A by 1032 bp band was observed 
after digestion by BamHI and EcoRI and 
electrophoresis.  
 To ensure of subcloning Ag85A into pcDNA 
cfp10 after ligation, pcDNA Ag85A/cfp10 vector was 
digested by the BamHI and EcoRI enzymes. The 
result was the 5731 bp fragment of digested 
pcDNA/cfp10 and the 1032 bp was attribute of 
digested Ag85A (Figure 1). 
The digestion of extracted 
pcDNA/Ag85A/cfp10 vector was also carried out 
with BamHI and XbaI. 
The ligation of them and then transformation 
into E. coli were performed so the results showed 
that the some bacterial cells included pCDNA 
Ag85A/cfp10 vector because the colony-PCR for 
cfp10 fragment was correctly done (Figure 2). 
The sequencing was also done by T7 and BGH 
primers. For sequencing assurement the software was 
DNAMAN. The sequence of fusion fragment was 
correct according NCBI database. 
The total RNA isolated from HeLa cell lines 
and cDNA was synthesized with reverse transcriptase 
and then used for PCR analysis. 
We determined the consensus sequence of 
cfp10 in pCDNA Ag85A/cfp10 in two different ways. 
In one approach, we directly sequenced PCR 
products amplified after RT-PCR. Analysis of the 
results showed the sequence of cfp10 was correct. In 
the second approach, PCR products amplified after 
RT-PCR, were run on agarose gel and were observed 
303bp strand. It is noted that the negative control 
samples did not have any strand attribute of cfp10. 
Discussion 
This ability of DNA vaccines to elicit both the 
arms of adaptive immunity humoral as well as cell 
mediated immune response, makes them one of the 
most promising vehicles for antigen delivery and 
prolonged  expression of antigen leads to the 
production of immunological memory (21, 22). 
The vector pcDNA3.1 (+) as a vector for our 
designing contains the cytomegalovirus immediate 
early promoter upstream and a bovine growth 
hormone polyadenylation sequence downstream of the 
gene of interest. The foreign gene can be inserted in 
frame between T7 and BGH promoter. 
We fused on two fragments cfp10 and Ag85A in 
this vector. CFP10 is a protein that is highly 
susceptible to proteolysis by trypsin digestion.  CFP10 
is completely destroyed at 4 ° C temperature for 20 
min. This protein is highly sensitive due to its 
unstructured form (23). Three members of Ag85 
family are distinguished by different isoelectric points. 
Monoclonal antibodies against Ag85 in BCG could 
have cross-reactivity with Ag85 epitopes of M. 
tuberculosis and M. leprae (24). 
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 The incidence of immune against Ag85 
complex was examined.  The plasmids encoding the 
Ag85A and Ag85B induced the production of TNFα, 
IL-2, IFNγ but the plasmid encoding Ag85C was non 
effective (25) therefore, we selected Ag85A that 
induce high immunity. 
In our previous study, we designed cfp10 in 
pcDNA3.1 and cloned in E. coli strain JM109 (20) 
therefore we expanded the work by synthesis a fusion 
two immunogenic gene containing cfp10 and Ag85A 
for better inducing of immune system. 
Antigenic epitopes containing Ag85A/B, 
ESAT6 and CFP10 for ECANS DNA vaccine were 
assigned. These genes were inserted into the hsp60 of 
the M. tuberculosis genome. Their results showed 
that T cell responses against the multiepitope DNA 
vaccine is a stronger than one gene (26), however we  
did not measure T cell responses in vivo, but we 
detected production of RNA that related to our 
targets. 
In 2013 the genes encoding Ag85A/MPT64 
were amplified by PCR from the genome of M. 
tuberculosis strain H37Rv and it was cloned in the 
eukaryotic expression vector and then digested with 
restriction enzymes and this was confirmed by DNA 
sequencing. The recombinant vector immunogenicity 
in BALB/c mice were tested and antibody titers were 
measured by ELISPOT method and their results were 
compared with the control group showing an increase 
in immune (23), perhaps fusion cfp10 and Ag85A to 
be better. We did not inject the DNA vaccine to 
mouse. 
The research was conducted by Macedo et al., 
in 2010 in Brazil. They examined the stimulation of 
cellular and humoral immunity against antigens 
Ag85A, Ag85B and ESAT6 of M. tuberculosis that it 
was in patients with pulmonary tuberculosis, extra-
pulmonary TB patients receiving chemotherapy and 
in healthy uninfected individuals. Their results 
showed that the IgG1 response against Ag85B and 
ESAT6 were elevated in patients compared to 
healthy controls. TNFα levels are increased in 
patients with pulmonary tuberculosis while in 
patients with pulmonary tuberculosis receiving 
chemotherapy high levels of IFNγ was observed. 
This difference was significant in distinguishing 
patients. According to this study for patient 
recognition , we can examine the production of IFNγ, 
TNFα and IgG1 in future against Ag85A and CFP10 
antigens (27). 
In general, we cloned the two genes in an 
eukaryotic vector and confirmed RNA expression by 
RT-PCR in HeLa cells. HeLa cell as an eukaryotic cell 
was important in our study. The mRNA presence of 
the fusion protein was detected in HeLa, so we can 
investigate the fusion protein and interferons in future 
studies. 
Conclusion 
In current study, the cfp10 and Ag85A genes of 
M. tuberculosis were cloned into a eukaryotic plasmid 
for construction a fusion DNA vaccine. 
The fusion fragment was sequenced, so the 
result was correct after analysis with software. The 
mRNA related to fusion fragment by RT-PCR was 
detected. 
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